Paula’s efforts will support and impact the lives of these young girls and their communities and help create equal opportunities for women across STEM industries. It’s a true example of how our teams advance DuPont’s commitment to diversity and inclusion.

WILMINGTON, Del. (PRWEB)
October 23, 2019

While roughly one-third of girls say they have considered a STEM career, only one-quarter actually pursue that path.(1) DuPont Nutrition & Biosciences is looking to change that statistic by creating equal opportunities across the scientific industry. Part of these efforts includes empowering its employees to drive the mission forward, and Paula Garcia Todd will do just that as a recently selected IF/THEN® ambassador of the American Association for the Advancement of Sciences (AAAS).

Garcia Todd, Global Strategic Marketing Manager, Drug Delivery Technologies, DuPont Nutrition & Biosciences, will bring her passion for science and mentoring to the next generation of STEM women through her year-long ambassadorship. As a first step, the ambassadors will connect with middle-schoolers both in person and through online platforms to serve as their personal mentor. Using the $5,000 ambassador stipend, Paula will work with teachers to create solutions to identify and access STEM corporate outreach programs like those offered through DuPont.

“Growing up in a family of engineers, I was constantly surrounded by examples of how those who worked in STEM improved the lives of others,” Garcia Todd said. “That inspiration led me to the pharmaceutical space, and as an IF/THEN® ambassador, I hope to introduce young women to the magic that happens when the impossible is met with innovative solutions.”

The IF/THEN® initiative was created by AAAS and Lyda Hill Philanthropies to empower innovators to use their firsthand experiences in the field to inspire and motivate middle-school girls to seek STEM careers. More than 100 women were selected for the initiative to serve as the first group of ambassadors based on their contributions to advance the industry; experience in communication and public engagement via media, classroom, and public programs; and their desire to impact youth.

“Paula’s efforts will support and impact the lives of these young girls and their communities and help create equal opportunities for women across STEM industries,” said Angela Strzelecki, Global Business Director, Pharma Solutions, DuPont Nutrition & Biosciences. “It’s a true example of how our teams advance DuPont’s commitment to diversity and inclusion, and I’m thrilled to see how Paula will help contribute.”

Throughout her 16 years with DuPont, and previously Dow, Garcia Todd has been an asset to driving pharmaceutical product innovation and a champion for diversity and inclusion efforts. She has contributed expertise through roles in engineering, research and development, technical support and various marketing and product management positions. In addition to her role at DuPont where she directs new product strategy and identifies pharmaceutical needs to accelerate customer growth and innovation, Garcia Todd volunteers in college environments and local communities and serves on several Boards focused on increasing STEM opportunities.

Garcia Todd and her fellow ambassadors will be celebrated for their achievements and initiated into the program at the IF/THEN® Summit in Dallas next week, where they’ll collaborate on ways to encourage, coach and influence their mentees during their yearlong commitment. In addition to these honorees, AAAS collaborates with dozens of organizations including Girl Scouts of the USA, National Geographic, Teach for America, U.S. Soccer and the World Wildlife Fund to further promote women in STEM among young girls.

DuPont also will sponsor the CPhI Worldwide ‘Women in Leadership Forum’ in early November where Strzelecki will join other industry leaders to discuss how to build a workforce where women are supported, emboldened and empowered to excel around the globe. To learn more about DuPont’s diversity and inclusion efforts, please visit: https://www.dupont.com/careers/diversity-and-inclusion.html.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandhealth.com or http://www.biosciences.dupont.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at http://www.dupont.com.

# # #

10/23/19

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

(1) Geena Davis Institute and Lyda Hill Foundation study

Share article on social media or email:

Mindray’s TE7 Ultrasound System Crystal Series

“Through a partnership with Mindray, I have gained access to incredible life-saving technologies.” – Dr. Robert Reardon, MD of Emergency Medicine at Hennepin County Medical Center, Minnesota’s first Level 1 Trauma Center

MAHWAH, N.J. (PRWEB)
October 23, 2019

Mindray, a global developer of technologies and solutions for patient monitoring, anesthesia and ultrasound, today announced they will be attending the American College of Emergency Physicians (ACEP) 2019 Scientific Assembly to highlight their advanced cardiac capabilities. ACEP, the world’s largest emergency medicine conference, will take place from October 27-30 in Denver, Colorado. Mindray will feature live scanning and an in-booth presentation on Tissue Tracking technology by Dr. Robert Reardon, MD of Emergency Medicine at Hennepin County Medical Center, Minnesota’s first Level 1 Trauma Center. All ACEP attendees are invited to visit exhibit #221 to learn more about Mindray’s complete range of advanced emergency medicine solutions.

Over the past 20 years, ultrasound has become an integral part of emergency departments, particularly for use with patients experiencing cardiac arrest. At the ACEP Scientific Assembly, Mindray will highlight its three primary point-of-care ultrasound systems, TE7, M9 and ZS3, each of which is equipped with advanced cardiac capabilities and transesophageal echocardiography (TEE) technology.

According to the American College of Emergency Physicians, “ultrasound has been shown in cardiac arrest to accurately identify the presence or lack of intrinsic cardiac activity and in some cases the cause of arrest, including left ventricular failure, right ventricular failure, pulmonary embolism, pericardial tamponade, and hypovolemia¹.” The College also observed that TEE allows emergency physicians to continuously monitor the patient without interrupting chest compressions during a cardiac arrest¹.

Mindray’s advanced single crystal transducers with 3T technology™ allow the end-user to scan at higher frequencies without the loss of penetration, thus bringing large cart-based image resolution to the point-of-care setting. Accompanying Tissue Tracking technology with quantitative analysis allows users to monitor the displacement of cardiac tissue by tracking the speckle displacement in the image from frame to frame. This advanced technology brings quantitative cardiac dysfunction assessment tools to the bedside.

“Through a partnership with Mindray, I have gained access to incredible life-saving technologies,” says Dr. Reardon. “I am passionate about assuring that every one of my patients receives the highest quality emergency care, and Mindray’s ultrasound systems empower me to provide care above and beyond the industry standard. Their mission to put healthcare within reach is evident in all that they do to support my team and me.”

Also on display will be Mindray’s new BeneVision N-Series Patient Monitoring Platform, the first-ever patient monitoring platform to incorporate capacitive touchscreen technology across all of its monitors. Using its unique multi-gesture touch and swipe control, similar to a smart device, clinicians can cut minutes off of clinical review, analysis and charting time. Applying the same user interface across the entire suite, N-Series supports unprecedented usability and clinical proficiency. Additionally, with the clever N1 3-in-1 monitor at the core, serving as both monitor and module and with wireless capability, N1 provides gap-free monitoring from the point of admission to discharge.

Visit ACEP exhibit #221 to see all that Mindray North America can offer an emergency department.

Mindray is a leading developer, manufacturer and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of life-saving tools across three primary business segments: patient monitoring and life support, In Vitro diagnostics, and medical imaging. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in San Jose, California with additional facilities in major international markets around the world. For more information, please visit http://www.mindray.com.

[1] American College of Emergency Physicians. (207, April). Guidelines for the Use of Transesophageal Echocardiography (TEE) in the ED for Cardiac Arrest [Policy Statement]. Retrieved from https://www.acep.org/globalassets/new-pdfs/policy-statements/guidelines-for-the-use-of-transesophogeal-echocardiography-in-the-ed-for-cardiac-arrest.pdf

Share article on social media or email:

Charles E. Crutchfield III, M.D.

“I am honored to have been selected by my peers as a Top Doctor for Women. There is nothing more humbling than to be recognized by my colleagues for quality service to patients and the best skin care in Minnesota. I truly appreciate their recognition and confidence in naming me for this honor.”

EAGAN, Minn. (PRWEB)
October 23, 2019

Dermatologist Charles E. Crutchfield III M.D. has been selected by a vote of his peers as one of the Top Doctors for Women for 2020 that will be reported in Minnesota Monthly’s 2020 January/February issue.

In an independent survey of all certified and practicing doctors within the 11-county metro area, as well as Olmstead County, thousands of votes were cast honoring excellence in the medical field and those that garnered the most votes were honored with this award. According to Minnesota Monthly, “Over 10,000 physicians are asked to nominate their peers for this prestigious honor.”

Amazingly, Dr. Crutchfield has been the only dermatologist awarded this honor every year the poll has been taken by Minnesota Monthly magazine beginning in 2006.

Dr. Crutchfield is the Medical Director of Crutchfield Dermatology and is a Clinical Professor of Dermatology at the University of Minnesota Medical School, as well as a Benedict Distinguished Visiting Professor of Biology at Carleton College. Dr. Crutchfield specializes in the treatment of skin-of-color/ethnic skin concerns, acne, psoriasis, vitiligo, atopic dermatitis and aesthetic/cosmetic dermatology.

“I am honored to have been selected by my peers as a Top Doctor for Women. There is nothing more humbling than to be recognized by my colleagues for quality service to patients and the best skin care in Minnesota. I truly appreciate their recognition and confidence in naming me for this honor,” said Dr. Crutchfield.

About Charles E. Crutchfield III, MD:

Charles E. Crutchfield III, M.D. is a graduate of the Mayo Clinic Medical School and a Clinical Professor of Dermatology at the University of Minnesota Medical School. Dr. Crutchfield is an annual selection in the “Top Doctors” issue of Mpls. St. Paul magazine. He is the only dermatologist to have been selected as a “Best Doctor for Women” by Minnesota Monthly magazine since the inception of the survey. Dr. Crutchfield has been selected as one of the “Best Doctors in America,” an honor awarded to only 4% of all practicing physicians. Dr. Crutchfield is the co-author of a children’s book on sun protection and dermatology textbook. He is a member of the AΩA National Medical Honor Society, an expert consultant for WebMD and CNN, and a recipient of the Karis Humanitarian Award from the Mayo Clinic School of Medicine.

Crutchfield Dermatology is a proud member of Doctors for the Practice of Safe and Ethical Aesthetic Medicine (DPSEAM). DPSEAM is limited to board-certified physicians who maintain the appropriate physician – patient relationship by having a medical director or licensed physician on site during all treatments including laser and injection services, require that a qualified physician examines every patient before the initial treatment or course of treatment, analyze patients’ pre-existing conditions or contradictions that would render the procedure unsafe or ineffective, create care plans that demonstrate how and why patients will benefit from planned procedures, and maintain an environment where patients feel free to ask questions and secure additional information about expected outcomes, among other requirements that protect cosmetic patients.

Crutchfield Dermatology is located at 1185 Town Centre Dr., suite 101, Eagan, Minnesota.

Please call 651-209-3600 for more information, or visit their website at http://www.crutchfielddermatology.com

Share article on social media or email:

[This research] suggests an entirely new route by which alcohol directly affects the brain via the ACSS2 enzyme and causes alcohol-related learning. Targeting this route could eventually aid in treating alcohol use disorder (AUD) and fetal alcohol syndrome (FAS).

PHILADELPHIA (PRWEB)
October 23, 2019

EpiVario, Inc., an early-stage drug discovery and development company, today announced results published in Nature, co-authored by the co-founders of EpiVario, which showed that alcohol consumption directly influences epigenetic regulation essential to memory formation. Through this metabolic route to epigenetic regulation, the studied animals showed preference for alcohol when exposed to environmental cues to consume alcohol; and when this metabolic route was blocked, this preference was eliminated.

The underlying study was conducted at the Perelman School of Medicine at the University of Pennsylvania and was led by Co-Founder Shelley Berger, PhD, Daniel S. Och University Professor and Director of the Penn Epigenetics Program, and Co-Founder Philipp Mews, PhD, who is now a postdoctoral fellow at The Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai in New York.

The research used isotopically-labeled alcohol and advanced mass spectrometry to track where the alcohol, and its breakdown products, go in the body and the brain. By doing so, metabolized alcohol was discovered to rapidly impact histone acetylation in the hippocampus – the learning and memory center of the brain – by directly depositing alcohol-derived acetyl groups onto histones via an enzyme called acetyl-CoA synthetase 2 (ACSS2).

Previous research conducted in the Berger lab, and led by Dr. Mews, found that ACSS2 is a key metabolic enzyme that works directly within the nucleus of neurons to turn genes on when new memories are being established.

“Our team in the Berger lab had previously discovered that ACSS2 ‘fuels’ a whole new machinery of gene expression ‘on-site’ in the nucleus of brain cells to turn on key memory genes after learning,” said Dr. Mews of the work that was published in a 2017 Nature paper. “We learned then that the metabolic factor ACSS2 is needed to lay down new memories.”

Combined with the results of the current study, this suggests an entirely new route by which alcohol directly affects the brain via the ACSS2 enzyme and causes alcohol-related learning. Targeting this route could eventually aid in treating alcohol use disorder (AUD) and fetal alcohol syndrome (FAS).

Memories associated with alcohol consumption are a primary driver of alcohol use disorder. According to the National Institute on Alcohol Abuse and Alcoholism, the disorder affects 15.1 million people in the United States alone, with the cost of alcohol misuse hovering at $250 billion.

“To our knowledge, this data provides the first empirical evidence indicating that a portion of the chemicals called acetate derived from alcohol metabolism directly influences epigenetic regulation in the brain,” said Dr. Berger. “The team was surprised to find that metabolized alcohol is directly used by the body to add acetyl groups to the proteins that package DNA, called histones, which is a key component in the memory formation process.”

In the current study, mice were exposed to neutral and alcohol reward spaces in designated compartments of their living environment to better understand how memories of alcohol-associated cues can affect behavior. The mice were allowed to roam free and researchers recorded the amount of time spent in either compartment. Mice with normal ACSS2 activity in their brains spent more time in the alcohol compartment. However, when ACSS2 in the brain was reduced, their preference for the alcohol compartment was not favored over the neutral compartment.

“This is significant because in alcohol use disorders, memory of alcohol-associated cues is a primary driver of craving and relapse, even after prolonged periods of abstinence,” said Dr. Mews. “Our latest findings establish a direct link between alcohol metabolism and histone acetylation in the hippocampus, indicating that translational treatment strategies that target this metabolic-epigenetic nexus may pave the way for novel therapeutic interventions for alcohol use and other neuropsychiatric disorders.”

The study also looked at the effects of alcohol consumption on developing mice by examining pregnant mice. After exposing the pregnant mice to ‘binge-drinking’ levels of alcohol, researchers identified deposits of alcohol-derived acetyl-groups onto histones in the fetal brains. These findings could eventually support the treatment and prevention of fetal alcohol syndrome, a cause of postnatal developmental disorders.

Thomas Kim, President and CEO of EpiVario, expressed the excitement over this data, saying, “The results further show the importance of ACSS2 as a target for preventing the storage of unwanted memories, in this case the cravings for alcohol triggered by environmental cues.”

EpiVario exclusively licensed the intellectual property related to this work from the University of Pennsylvania. In addition to their current work on the development of a treatment for AUD, EpiVario is also developing a small molecule therapeutic for PTSD.

About EpiVario, Inc.

EpiVario is an early-stage drug discovery and development company that targets a wide range of memory-related psychiatric disorders, including PTSD, Alzheimer’s, and alcohol and drug addiction. The Company’s novel approach targets memory formation at the source of the disease, preventing the creation and reconsolidation of traumatic memories. Core to EpiVario is administering its drug in conjunction with psychotherapy, where a negative or traumatic memory is intentionally re-lived, with the goal of disassociating the stress linked to the original traumatic event. EpiVario is a startup company originally founded at the Penn Center for Innovation. For more information visit http://www.epivario.com.

Share article on social media or email:

Board-Certified Oral Surgeon, Dr. Aaron Quitmeyer, Offers Harrisonburg, VA Sedation Dentistry

Dr. Quitmeyer takes every effort to make surgical treatment as safe, comfortable, and pain-free as possible with sedation services…

HARRISONBURG, Va. (PRWEB)
October 23, 2019

Board-certified oral surgeon, Dr. Aaron Quitmeyer, helps patients ease dental anxiety and fear with custom sedation dentistry at his Harrisonburg, VA practice. Dr. Quitmeyer takes every effort to make surgical treatment as safe, comfortable, and pain-free as possible with sedation services, including nitrous oxide, oral and IV sedation, and general anesthesia.

Patients with dental anxiety are often too fearful to undergo necessary dental treatment. Due to the nature of many oral and maxillofacial procedures, most patients feel apprehension about complex treatments such as wisdom teeth extraction, jaw surgery, and dental implant placement. In these circumstances, sedation dentistry plays a key role in helping patients feel calm and comfortable enough to receive treatment. Plus, it provides optimal pain control during surgery.

Dr. Quitmeyer offers a comprehensive range of sedation dentistry services at his practice, Shenandoah Oral and Facial Surgery, including nitrous oxide, oral sedation, IV sedation, and general anesthesia. Nitrous oxide, also known as “laughing gas”, is good for patients with mild anxiety, putting them in a comfortable, relaxed state. For moderate anxiety, oral sedation is anti-anxiety medication taken in pill form before a procedure, putting patients in a drowsy, calm state. IV sedation, a helpful option for patients with high anxiety, is administered intravenously and has amnesic effects. Though patients remain conscious and responsive during IV sedation treatments, they have no recollection of the treatment. General anesthesia is controlled unconsciousness for patients with severe phobias or those needing intense surgical treatment. General anesthesia is typically only available at hospitals, but because of Dr. Quitmeyer’s education and expertise, he is able to administer it in office.

Dr. Quitmeyer has undergone advanced training in anesthesia and sedation and is certified to provide all levels of sedation dentistry comfortably at his modern practice. With expertise in the full scope of oral and maxillofacial surgery, he and his team provide the ideal setting for patients needing sedation dentistry. When comfortably sedated, patients can receive treatment like dental implant placement, jaw surgery, bone grafting, and more to restore ideal dental health, oral function, and facial aesthetics.

Patients with anxiety or phobia about undergoing dental surgery can benefit from sedation dentistry at Dr. Quitmeyer’s Harrisonburg, VA practice. Consultations with the oral surgeon can be made by calling 540-433-1751 or visiting http://www.shenandoahofs.com.

About the Practice

Shenandoah Oral and Facial Surgery offers oral and maxillofacial surgical care to the greater Shenandoah Valley. A board-certified oral surgeon, Dr. Aaron Quitmeyer serves a full scope of oral surgical treatments. Always welcoming, he and his team emphasize patient education, encouraging each patient to feel empowered to choose the right care for them. Implementing the latest technology every step of the way, they offer custom oral surgical treatments including wisdom teeth extractions, jaw surgery, dental implants and full mouth reconstructions to restore health, function and aesthetics. Dr. Quitmeyer is proud to call the Shenandoah Valley his home after a rewarding 10-year career in the United States Navy Dental Corps. To learn more about Dr. Quitmeyer, his practice, or the services they offer, visit http://www.shenandoahofs.com or call their office in Harrisonburg, VA at 540-433-1751.

Share article on social media or email: